Apertor Pharmaceuticals, Inc. — Form D
Apertor Pharmaceuticals, Inc. of NEW YORK, NY, a company, filed a Form D exempt-offering notice with the SEC on 2020-11-17. The offering totals $50.0M, of which $3.0M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2020-11-17
- Form: D
- Accession: 0001832728-20-000001
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $50.0M
- Amount sold: $3.0M
- Remaining: $47.0M
- Investors: 1
- Date of first sale: 2020-11-05
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-380841
Issuer
- Name: Apertor Pharmaceuticals, Inc.
- CIK: 0001832728
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2020
- Address: 230 PARK AVENUE, NEW YORK, NY, 10169
- Phone: (857) 352-3657
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| Robert T Abraham | Director | New York, NY |
| Paul Eisenberg | Director | New York, NY |
| Edmund Graziani | Director | New York, NY |
| Seth Harrison | Director | Redwood City, CA |
| Spiros Liras | Director | New York, NY |
| Edmund Graziani | Executive Officer | New York, NY |
| Spiros Liras | Executive Officer | New York, NY |
More